MedPath

ROBAXIN

ROBAXIN Injectable (methocarbamol injection, USP)

Approved
Approval ID

090a3d3d-92c3-4c30-a648-436461f81702

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 18, 2024

Manufacturers
FDA

Hikma Pharmaceuticals USA Inc.

DUNS: 946499746

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

methocarbamol

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0641-6103
Application NumberNDA011790
Product Classification
M
Marketing Category
C73594
G
Generic Name
methocarbamol
Product Specifications
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateJanuary 18, 2024
FDA Product Classification

INGREDIENTS (5)

HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
METHOCARBAMOLActive
Quantity: 100 mg in 1 mL
Code: 125OD7737X
Classification: ACTIB
POLYETHYLENE GLYCOL 300Inactive
Quantity: 0.5 mL in 1 mL
Code: 5655G9Y8AQ
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ROBAXIN - FDA Drug Approval Details